Hsbc Holdings PLC Takes Position in AnaptysBio, Inc. $ANAB

Hsbc Holdings PLC purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 125,717 shares of the biotechnology company’s stock, valued at approximately $7,137,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. AQR Capital Management LLC raised its stake in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 18,165 shares during the last quarter. Creative Planning increased its holdings in shares of AnaptysBio by 26.9% during the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after acquiring an additional 3,571 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after acquiring an additional 233,325 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of AnaptysBio in the 2nd quarter valued at approximately $528,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of AnaptysBio in the 2nd quarter valued at approximately $3,348,000.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ANAB. Zacks Research downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings lowered shares of AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. UBS Group increased their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Piper Sandler cut their price target on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Finally, Barclays upped their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $82.00.

AnaptysBio Stock Performance

ANAB opened at $54.91 on Friday. The company has a fifty day moving average of $58.56 and a two-hundred day moving average of $57.50. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -50.84 and a beta of 0.68. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -1.35 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has initiated a stock buyback plan on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.